ARGX ARGENX SE IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1697862 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY89.9%
TTM net income YoY55.1%
TTM EPS YoY53.1%
Revenue 3-yr CAGR118.0%
Net income 3-yr CAGR—
Margins
Gross margin89.1%
Operating margin25.4%
Net margin31.1%
FCF margin16.4%
EBITDA margin—
Returns
ROE20.2%
ROA17.4%
ROIC (approx.)26.9%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets15.7%
Debt / equity0.00x
Current ratio5.23x
Interest coverage258.16x
Cash quality & payout
Operating cash flow / net income0.53x
Accruals ratio8.2%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.15B | $2.19B |
| Cost of revenue | $450.67M | $227.29M |
| Gross profit | $3.70B | $1.96B |
| R&D expense | $1.36B | $983.42M |
| SG&A expense | $1.37B | $1.06B |
| Operating income | $1.05B | -$21.65M |
| Interest expense | $4.08M | $2.46M |
| Pretax income | $1.28B | $85.18M |
| Income tax | -$13.43M | -$747.86M |
| Net income | $1.29B | $833.04M |
| EPS (basic) | 21.08 | 13.92 |
| EPS (diluted) | 19.57 | 12.78 |
| Weighted avg. shares (diluted) | 66.03M | 65.18M |
| Balance sheet | ||
| Cash & equivalents | $3.49B | $1.50B |
| Receivables | $1.65B | $904.47M |
| Inventory | $473.53M | $407.23M |
| Current assets | $6.90B | $4.88B |
| PP&E, netmay include right-of-use assets (IFRS) | $48.25M | $43.52M |
| Intangibles | $272.10M | $181.44M |
| Total assets | $8.68B | $6.20B |
| Current liabilities | $1.32B | $669.92M |
| Total liabilities | $1.36B | $704.24M |
| Shareholders' equity | $7.32B | $5.50B |
| Shares outstanding | 61.88M | 60.76M |
| Cash flow statement | ||
| Operating cash flow | $685.19M | -$82.75M |
| Capital expenditure | $6.17M | $1.80M |
| Free cash flow | $679.03M | -$84.55M |
| Investing cash flow | $984.00M | -$717.59M |
| Financing cash flow | $233.01M | $279.76M |
| Stock-based compensation | $248.08M | $235.18M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.